Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by DavidKingCanadaon Sep 26, 2021 12:22pm
123 Views
Post# 33920721

RE:RE:RE:RE:RE:fidelity?

RE:RE:RE:RE:RE:fidelity?

Trek, couple of points since you seem new to the Forum;

- You think the Boston Group has found a  Gem in PMN and will 20 times their Profit while the Retail Investors sit on the sidelines? How confident was the Boston Group in choosing only PMN has their lord and saviour?

- Many of you are thinking that Buying now at 0.18 you will 20 times your Investment because the Boston Group owns 25% of PMN. 

- There are many Investors in this Forum that have been Investing in PMN for more than 10 Years without any substantial Gains.

- Don't believe anyone on this Forum when they state they have more than a Million Shares of PMN. Thats close to $200,000.00 as of now. What imbecile Invests 200K into a high risk penny stock? No Retail Investor would do that without having Inside Information. No one in this Board has Inside Information.

- There are NO Medical Professionals on this Forum, take everyone DD with a grain of salt. 

<< Previous
Bullboard Posts
Next >>